Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 4/20 | 0.33 |
| ▸ | ADH1C | P00326 | 3/20 | 0.33 |
| ▸ | ADH1B | P00325 | 2/20 | 0.33 |
| ▸ | ADH4 | P08319 | 2/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861049 | 0.75 | — | — | |
| SCHEMBL28515037 | 0.70 | — | — | |
| Cyclopentanecarbaldehyde SCHEMBL14575123 | 0.67 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL11341547 | 0.67 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL11734533 | 0.67 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| Cycloheptane Carbaldehyde SCHEMBL95620 | 0.67 | — | — | |
| SCHEMBL493755 | 0.67 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL59918 | 0.67 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL329469 | 0.67 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 | |
| Cyclononanecarbaldehyde SCHEMBL1920808 | 0.67 | ADH1A (0.41) | ADH1AADH1CADH1BADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105324378-A | Quinazolinone derivatives useful as FGFR kinase modulators | ASTEX THERAPEUTICS LTD | 2016-02-10 | — | — | CN | disclosed |
| CN-101754769-B | Use of type B lantibiotics based on antimicrobial activity | NOVACTA BIOSYSTEMS LTD. (GB) | 2015-09-09 | — | — | CN | disclosed |
| CN-104837835-A | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LTD | 2015-08-12 | — | — | CN | disclosed |
| CN-103492376-B | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LTD | 2015-07-22 | — | — | CN | disclosed |
| CN-104736533-A | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LTD | 2015-06-24 | — | — | CN | disclosed |
| CN-104725362-A | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD | 2015-06-24 | — | — | CN | disclosed |
| CN-104507944-A | Pteridines as FGFR inhibitors | ASTEX THERAPEUTICS LTD | 2015-04-08 | — | — | CN | disclosed |
| CN-104507931-A | New compounds | ASTEX THERAPEUTICS LTD | 2015-04-08 | — | — | CN | disclosed |
| CN-102858765-B | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD | 2015-04-01 | — | — | CN | disclosed |
| CN-102131791-B | Dibenzothiepiazane derivatives and their use | ASTRAZENECA SWEDEN AB | 2014-12-24 | — | — | CN | disclosed |
| WO-2007058990-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-5977136-A | Tetrahydroquinolines as NMDA antagonists | GLAXO WELLCOME SPA (IT) | 1999-11-02 | — | — | US | disclosed |